Literature DB >> 2460924

Fidelity of HIV-1 reverse transcriptase.

B D Preston1, B J Poiesz, L A Loeb.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) shows extensive genetic variation and undergoes rapid evolution. The fidelity of purified HIV-1 reverse transcriptase was measured during DNA polymerization in vitro by means of three different assays. Reverse transcriptase from HIV-1 introduced base-substitution errors in DNA from the bacteriophage phi X174 amber3 at estimated frequencies of 1/2000 to 1/4000. Analyses of misincorporation rates opposite a single template adenine residue showed that HIV-1 reverse transcriptase catalyzed nucleotide mismatches with a specificity of A:C much greater than A:G greater than A:A. The high error rate of HIV-1 reverse transcriptase in vitro translates to approximately five to ten errors per HIV-1 genome per round of replication in vivo. This high error rate suggests that misincorporation by HIV-1 reverse transcriptase is, at least in part, responsible for the hypermutability of the AIDS virus. The specificity of misincorporation may provide a basis for the systematic construction of antiviral nucleosides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460924     DOI: 10.1126/science.2460924

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  276 in total

1.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.

Authors:  Michael R Jordan; Mary Kearney; Sarah Palmer; Wei Shao; Frank Maldarelli; Eoin P Coakley; Colombe Chappey; Christine Wanke; John M Coffin
Journal:  J Virol Methods       Date:  2010-05-06       Impact factor: 2.014

3.  K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies.

Authors:  Scott J Garforth; Robert A Domaoal; Chisanga Lwatula; Mark J Landau; Amanda J Meyer; Karen S Anderson; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2010-06-09       Impact factor: 5.469

4.  Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.

Authors:  H Sato; Y Tomita; K Ebisawa; A Hachiya; K Shibamura; T Shiino; R Yang; M Tatsumi; K Gushi; H Umeyama; S Oka; Y Takebe; Y Nagai
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Controlling the Evolution of Resistance.

Authors:  Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski
Journal:  J Process Control       Date:  2011-03-01       Impact factor: 3.666

Review 6.  Retrons and multicopy single-stranded DNA.

Authors:  M Inouye; S Inouye
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

7.  Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.

Authors:  C J Chen; A C Banerjea; G G Harmison; K Haglund; M Schubert
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

8.  Mechanism analysis indicates that recombination events in HIV-1 initiate and complete over short distances, explaining why recombination frequencies are similar in different sections of the genome.

Authors:  Sean T Rigby; April E Rose; Mark N Hanson; Robert A Bambara
Journal:  J Mol Biol       Date:  2009-02-20       Impact factor: 5.469

9.  Lethal mutagenesis of HIV with mutagenic nucleoside analogs.

Authors:  L A Loeb; J M Essigmann; F Kazazi; J Zhang; K D Rose; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 10.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.